Human anti-HEV IgG ELISA Kit (IVDEIA005)

Regulatory status: For research use only, not for use in diagnostic procedures.

Write a review

Size
96T
Sample
serum, plasma
Species Reactivity
Human
Intended Use
The Human HEV-IgG ELISA Kit is an enzyme-linked immunosorbent assay for the qualitative detection of IgG-class antibodies to hepatitis E virus in human serum or plasma. It is intended to be used as an aid in supplementary diagnosis to acute hepatitis E infection and prevalence studies among the population.
Contents of Kit
1. Microwell plate: 1 x 96 wells
2. Negative control: 1 x 0.5 mL
3. Positive control: 1 x 0.5 mL
4. Specimen diluent: 1 x 12 mL
5. HRP-conjugate: 1 x 12 mL
6. Wash buffer (20X): 1 x 50 mL
7. Chromogen solution A: 1 x 7 mL
8. Chromogen solution B: 1 x 7 mL
9. Stop solution: 1 x 7 mL
Storage
The components of the kit will remain stable through the expiration date indicated on the label and package when stored at 2-8°C, do not freeze. For more detailed information, please download the following document on our website.

Citations


Have you cited IVDEIA005 in a publication? Let us know and earn a reward for your research.

Customer Reviews


Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket

References


A survey of powertrain configuration studies on hybrid electric vehicles

APPLIED ENERGY

Authors: Zhuang, Weichao; Li (Eben), Shengbo; Zhang, Xiaowu; Kum, Dongsuk; Song, Ziyou; Yin, Guodong; Ju, Fei

Global warming, air pollution, and fuel depletion have accelerated the deployment of hybrid electric vehicles (HEVs). Apart from the energy management, the configuration of hybrid powertrains plays a central role in achieving better fuel economy and enhanced drivability. This paper comparatively summarizes the configurations, modeling, and optimization techniques of HEVs. Four types of hybrid powertrain configurations available in the market, i.e., series, parallel, power-split and multi-mode, are introduced firstly, followed by their state-of-the-art and pros/cons. Among all configurations, multi-mode hybrid powertrains are observed to have the potential for utilizing the benefits of the other three types by switching the operating modes. Subsequently, the configuration generation and modeling techniques are summarized. By adopting the automated modeling method, the entire design space can be explored exhaustively, and 14 feasible configuration types are classified based on the binary tree. Finally, the research gaps and future trends of HEV configuration studies are discussed.

CRISPR-CAS Replacing Antiviral Drugs against HIV: An Update

CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION

Authors: Hashmat, Rabia; Yousaf, Muhammad Zubair; Rahman, Ziaur; Anjum, Khalid Mahmood; Yaqub, Atif; Imran, Muhammad

Various antiretroviral drugs do not kill or cure the human immunodeficiency virus (IIIV) but do prevent the replication of the virus. The combination of antiretroviral drugs is known as highly active antiretroviral therapy (HAART). Current drug therapies effectively suppress HEV-1 replication but do not inactivate the provirus that persists in latent reservoirs. Guide RNA (gRNA)-directed CRISPR/Cas9 system can be used for sequence-specific attacks on this proviral DNA. The biggest achievement might be the complete elimination of HIV from infected cells. A study revealed that the tail injection, in transgenic mice and rats having HIV-1 genome, of an adenoassociated virus (AAV) vector expressing a short version of the Cas9 endonuclease (saCas9) and the gRNAs resulted in the cleavage of integrated HIV-1 DNA and excision of a DNA fragment spanning between the LTR and Gag gene in the spleen, liver, heart, kidney, and circulating lymphocytes. HIV-1 has capacity to escape the attack on its genome from most of inhibitors. Thus, to achieve successful antiretroviral treatment, combinations of several antiviral therapies have been applied that are based on two important facts. The first is that multiple drugs lead to synergistic or additive inhibition, and the second is that the combinational therapy increases chances of drug resistance. The success that has been achieved with the help of the genetically engineered tool CRISPR is that dCas9 protein alone can efficiently silence viral gene expression in bacteria with sgRNA. All the reported investigations have indicated that CRISPR/Cas9 can be used as immune machinery into human cells in the form of novel antivirus tools.

Online Inquiry

Name:
Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:
Verification code
Click image to refresh the verification code.

Online Inquiry

  Interested in larger quantities ? request a quote!
  Protocol may be improved. Please feel free to contact us to obtain the latest version.!

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

OUR PROMISE TO YOU Guaranteed product quality expert customer support

Inquiry Basket